Informa Connect’s Life Science Partnering, Investment & Strategy teams' mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference portfolio in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today, our events (BIO-Europe, BIO-Europe Spring®, Biotech Showcase™, ChinaBio® Partnering Forum, Asia Bio Partnering Forum, LSX Europe, LSX Nordic, LSX USA, Investival Showcase EU, Investival Showcase USA, European Lifestars Awards, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
Informa is a leading international Live B2B Events, B2B Digital Services, and Academic Markets Group. We champion specialists: connecting businesses and professionals with knowledge to help them learn more, know more and do more. Informa is a member of the FTSE 100 and works in over 30 countries.
For more information, please visit: https://informaconnect.com/partnering-investment-strategy/
Informa is a leading international Live B2B Events, B2B Digital Services, and Academic Markets Group. We champion specialists: connecting businesses and professionals with knowledge to help them learn more, know more and do more. Informa is a member of the FTSE 100 and works in over 30 countries.
For more information, please visit: https://informaconnect.com/partnering-investment-strategy/
Inivata is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment.. . Inivata works with leaders in industry and academic research to develop new clinical applications for ctDNA analysis which will bring real benefits to physicians, patients, pharmaceutical companies and payers. Inivata’s goal is to provide physicians with the information they need, to provide the best outcomes for patients and effective design for clinical trials.. . Inivata is based in Cambridge, UK and its scientific founders are leading figures in the ctDNA field: Nitzan Rosenfeld (Cancer Research UK Cambridge Institute, University of Cambridge), Tim Forshew (UCL Cancer Institute, University College London), James Brenton (Cancer Research UK Cambridge Institute, University of Cambridge) and Davina Gale (Cancer Research UK Cambridge Institute, University of Cambridge).. . The Company has a comprehensive understanding of cancer genomics and circulating DNA. It is applying its enhanced TAm-Seq approach and cutting-edge technologies to address critical clinical decision points in cancer care and cancer drug development, alongside pharmaceutical partners, leading clinicians and academic groups.
No data available
No data available
No data available
IONTAS is a privately owned, profitable, biotechnology company, offering services and technologies to the global biotechnology community. Our expertise focuses on phage display and technologies for therapeutic antibody discovery. IONTAS scientific staff have been at the forefront of phage display technology, mammalian display and generating antibodies against ion channels
Intellectual property services. Chartered patent and trademark attorneys, intellectual property services.. . I.P.21 combine modern customer relationship management with the delivery of the highest quality intellectual property services. We have a strong biotechnology team experienced in all phases of patent protection from drafting and filing through to prosecution. In most cases, our patent services are offered on a fixed-fee basis.. .
No data available
Isogenica partners with leading pharmaceutical and biotechnology companies in the early-stage discovery of novel biopharmaceuticals. . . Isogenica’s partners can access a range of innovative, highly-diverse, antibody libraries as an excellent starting point for new biotherapeutic development programmes.. . All the company’s libraries are fully synthetic, designed using state-of-the-art principles and built using the company’s highly precise Colibra oligonucletotide contruction technology. The combination of advanced design and accurate synthetic build technology minimises immunological biases, inevitable when using in vivo systems, and optimises the chances of generating high-affinity and developable drug candidates at the outset.. . The company’s proprietary antibody libraries are complemented with the option to use a proprietary in vitro antibody display system (CIS Display) which maintains the high diversity of the library through the discovery process. CIS Display is also available for licensing as a standalone technology.. . Isogenica currently has a range of camelid single domain antibody (VHH) libraries, and a range of human antibody fragment libraries. The company continues to innovate in the design and construction of new, advanced antibody libraries.
No data available